Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24141251 | 0.81 | BACE1 (0.34) | — | |
| SCHEMBL25877483 | 0.77 | MAPT (0.43) | POLBMAPTLMNAHTTNPC1 | |
| SCHEMBL25877590 | 0.75 | MAPT (0.34) | POLBMAPTLMNAHTTALDH1A1 | |
| SCHEMBL25877480 | 0.74 | MAPT (0.38) | POLBMAPTRAB9AALDH1A1MAPK1 | |
| SCHEMBL30964077 | 0.72 | MAPT (0.54) | POLBMAPTLMNAHTTNPC1 | |
| SCHEMBL25877435 | 0.72 | ALDH1A1 (0.42) | POLBMAPTLMNAGAAALDH1A1 | |
| SCHEMBL25877451 | 0.71 | VCAM1 (0.44) | POLBMAPTLMNARAB9AALDH1A1 | |
| SCHEMBL25877386 | 0.70 | MAPK1 (0.47) | MAPTLMNANPC1RAB9AGAA | |
| SCHEMBL25877473 | 0.70 | LMNA (0.46) | POLBMAPTLMNAHTTGAA | |
| SCHEMBL25877891 | 0.70 | ALDH1A1 (0.53) | POLBMAPTLMNAHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | FEN1, ERCC4, DCLRE1B | POLB 64/4885MAPT 3694/4885LMNA 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.